Across-the-board sequestration cuts could hurt the FDA's efforts to accelerate new drug reviews, said FDA Commissioner Dr. Margaret Hamburg during MassBio's annual meeting. Hamburg said she hopes Congress will allow the agency to put user fees paid by drugmakers toward its operating expenses.
Sequestration threatens faster FDA reviews, Hamburg says
SmartBrief Job Listings for Health Care
|Manager of Provider Network Analytics||
Geisinger Health System
|Chief Operating Officer||
Presence Health Partners
|Des Plaines, IL|
|Sr. Business Systems Analyst||
|Sr. Reimbursement Analyst||
Olympus America Inc.